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Abstract
3,39-diindolylmethane (DIM), one of the active products derived from Brassica plants, is a promising antitumor agent. The
present study indicated that DIM significantly induced apoptosis in U937 human leukemia cells in dose- and time-
dependent manners. These events were also noted in other human leukemia cells (Jurkat and HL-60) and primary human
leukemia cells (AML) but not in normal bone marrow mononuclear cells. We also found that DIM-induced lethality is
associated with caspases activation, myeloid cell leukemia-1 (Mcl-1) down-regulation, p21
cip1/waf1 up-regulation, and Akt
inactivation accompanied by c-jun NH2-terminal kinase (JNK) activation. Enforced activation of Akt by a constitutively
active Akt construct prevented DIM-mediated caspase activation, Mcl-1 down-regulation, JNK activation, and apoptosis.
Conversely, DIM lethality was potentiated by the PI3K inhibitor LY294002. Interruption of the JNK pathway by
pharmacologic or genetic approaches attenuated DIM-induced caspases activation, Mcl-1 down-regulation, and
apoptosis. Lastly, DIM inhibits tumor growth of mouse U937 xenograft, which was related to induction of apoptosis
and inactivation of Akt, as well as activation of JNK. Collectively, these findings suggest that DIM induces apoptosis in
human leukemia cell lines and primary human leukemia cells, and exhibits antileukemic activity in vivo through Akt
inactivation and JNK activation.
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Introduction
Epidemiological studies have revealed an association between
high dietary intake of cruciferous vegetables and decreased cancer
risk [1]. The dietary indoles have been shown to be protective
against several types of cancers [2]. Indole-3-carbinol (I3C) and
3,39-diindolylmethane (DIM) are naturally occurring plant
alkaloids formed by the hydrolysis of indole glucosinolate
(glucobrassicin) and are found in abundance in cruciferous
vegetables such as broccoli and Brussels sprouts [3]. I3C is
chemically unstable in an acidic environment and is rapidly
converted to a variety of condensation products in the stomach.
Among those products, DIM is a major one that is readily
detectable in the liver and feces of rodents fed with I3C [4]. The
parent I3C could not be detected in tissues of I3C-treated rodents,
whereas DIM is acid stable and detectable in biological tissues
suggesting that DIM may mediate the physiologic effects of dietary
I3C [5], [6]. It has been shown that I3C and DIM exert
anticarcinogenic effects in experimental animals and humans [7],
[8]. Several studies have also shown that DIM is a potent inhibitor
of cell growth and inducer of apoptotic cell death in breast cancer
cells [9], [10]. Since DIM is relatively nontoxic to normal tissues of
animals and humans [11], it might play an important role in the
chemoprevention and chemotherapy of cancers. It has been
reported that consumption of cruciferous vegetables appeared to
be associated with a decreased risk of leukemia especially AML
[12]. Because DIM is a major component of cruciferous
vegetables, DIM would be a particularly effective agent for
leukemia.
The PI3K/Akt signaling pathway plays an important role in cell
survival and anti-apoptotic decisions [13]. A major activator of
Akt is phosphatidylinositol-3, 4, 5-triphosphate (PIP3) which is
generated by phosphatidylinositol-3- kinase (PI3K) [14]. Akt is
activated by phosphorylation at Thr308 by PDK1 or at Ser473 by
mTORC2 [15]. Activated Akt functions to promote cell survival
by inhibiting apoptosis through inactivation of several pro-
apoptotic factors including Bad, Forkhead transcription factors,
and caspase-9 [16], [17], [18]. Akt has been believed to be an
attractive target for cancer prevention or treatment.
c-Jun N-terminal kinase (JNK) belongs to the super family of
MAP kinases, which can promote apoptosis by different
mechanisms [19]. Activation of JNK may result in phosphoryla-
tion of c-Jun and activator protein-1 (AP-1) activity, which could
drive cells to apoptosis [20]. Previous studies on the role of cell
signaling cascades in DIM-mediated lethality have primarily
focused on those related to oxidative stress and cell signaling
pathways. For example, in MCF-7 human breast cancer cells,
DIM induced G1 cell cycle arrest through up-regulation of p21,
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31783and the oxidative stress and stress-activated signaling cascades
including p38 MAPK and JNK play the key roles in these events
[21]. It has also been shown that DIM induced apoptosis through
inactivation of NF-kB in human breast cancer cells [22]. In
cholangiocarcinoma cells, Fas mediated apoptosis was enhanced
by DIM through inhibition of Akt and FLIP [23]. Furthermore, in
human prostate cancer cells, DIM inhibited cell proliferation and
induced apoptosis through down-regulation of AR, Akt, and NF-
kB signaling [24]. However, neither the effects of DIM on
apoptosis induction nor the relationships between DIM lethality
and cell signaling cascades been examined in depth in human
leukemia. Here, for the first time we reported that DIM
significantly induced apoptosis in human leukemia cells. Our
results indicate that inactivation of Akt and activation of JNK play
important roles in DIM-mediated apoptosis in these cells. Our
results also indicate that DIM inhibits growth of mouse U937
xenograft tumors, and the interruptions of the Akt and JNK
pathways are involved in DIM-mediated antileukemic activity in
vivo.
Results
DIM induces apoptosis in U937 human leukemia cells in
dose- and time-dependent manners
Dose-dependent study revealed a moderate increase in
apoptosis 12 h and 24 h after exposure to DIM at concentration
of 60 mM and very extensive apoptosis at concentration of 80 mM
(Fig. 1a). Time-course study of cells exposed to 80 mM DIM
demonstrated a significant increase in apoptosis at 9 h after drug
exposure. These events became apparent after 12 h of drug
exposure, and reached near-maximal levels after 24 h (Fig. 1a).
Consistent with these findings, the same DIM concentrations and
exposure intervals resulted in cleavage/activation of caspase-3, -7,
-8 and -9, as well as PARP degradation (Fig. 1b).
Figure 1. DIM induces apoptosis, caspase activation, downregulation of Mcl-1, upregulation of p21, inactivation of Akt, and
activation of JNK in U937 human leukemia cells in dose- and time-dependent manners. U937 cells were treated with various
concentrations of DIM as indicated for 12 h and 24 h or treated with 80 mM DIM for 1, 3, 6, 9, 12, and 24 h. (a) Cells were washed twice with PBS and
stained with Annexin V/propidium iodide (PI), and apoptosis was determined using flow cytometry. Both early apoptotic (Annexin V-positive, PI-
negative) and late apoptotic (Annexin V-positive and PI-positive) cells were included in cell death determinations. The values obtained from annexin
V/PI assays represent the mean 6 SD for three separate experiments. (b–d) Total cellular extracts were prepared and subjected to Western blot assay
using antibodies as indicated.
doi:10.1371/journal.pone.0031783.g001
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of Mcl-1 and up-regulation of p21
The effects of DIM were then examined in relation to
expression of various Bcl-2 family members and cell cycle
regulatory protein. A dose-dependent study revealed that exposure
of U937 cells to DIM at concentration of 40 mM resulted in
decrease in expression of Mcl-1 and increase in expression of p21.
These events became very extensive at concentrations $60 mM
(Fig. 1c). Time-course study demonstrated that exposure of U937
cells to 80 mM DIM resulted in slight decrease in expression of
Mcl-1 as early as 1 h after drug exposure. This event became
apparent after 3 h of drug exposure, and the expression of Mcl-1
was complete blocked after 12 h (Fig. 1c). On the other hand,
exposure of cells to 80 mM DIM resulted in increase in expression
of p21 at 9 h after drug exposure, and this event became extensive
after 24 h of drug exposure (Fig. 1c). In contrast, exposure of cells
to DIM resulted in little or no change in expression of Bcl-2, Bcl-
xL, Bax, Bad, and Bim (data not shown).
DIM induces inactivation of Akt and activation of JNK in
U937 cells
Effects of DIM in U937 cells were also examined in relation to
various signaling pathways implicated in apoptosis regulation.
Exposure of cells to DIM for 12 h and 24 h resulted in diminished
phosphorylation of Akt in a dose-dependent manner. This event
was accompanied by a pronounced increase in phosphorylation of
JNK (Fig. 1d). Time-course study demonstrated that exposure of
cells to DIM (80 mM) resulted in inhibition of phosphorylation of
Akt and activation of JNK as early as 3 h after drug exposure.
These events became apparent at 6 h and very extensive at 12 h
and 24 h after drug exposure (Fig. 1d). In contrast, DIM had little
or no effect on expression of total or phospho-mTOR, ERK, or
p38 MAPK (data not shown). These results suggest that
inactivation of Akt and activation of JNK may play important
roles in DIM-induced apoptosis.
DIM has similar effects on apoptosis in Jurkat and HL-60
cells, and AML primary leukemia cells
To determine whether these events were restricted to myeloid
leukemia cells, parallel studies were performed in Jurkat and HL-
60 leukemia cells. These cells exhibited apoptotic effects upon
DIM exposure similar to those observed in U937 cells although
Jurkat and HL-60 cells are less sensitive than U937 cells in DIM-
induced apoptosis (p,0.01 versus control), PARP degradation,
caspases activation (Fig. 2a and 2b).
The effects of DIM on apoptosis in primary leukemia cells from
15 AML patients (four of those patients are M2, five are M4, and
six are M5 according to FAB classification system) were
Figure 2. DIM induces apoptosis in U937, Jurkat, and HL-60 cells, and in AML blast samples, but not in normal bone marrow
mononuclear cells. (a) U937, Jurkat, and HL-60 cells were treated with 80 mM DIM for 24 h, after which apoptosis was determined by annexin V/PI
staining and flow cytometry. ** Values for cells treated with DIM were significantly increased compared to values in control cells by Student’s t-test,
p,0.01. (b) Total cellular extracts were prepared and subjected to Western blot analysis using antibodies as indicated. (c–d) Blasts from 15 patients
with AML and normal bone marrow mononuclear cells were treated with 80 mM DIM for 24 hours, apoptosis was determined by annexin V/PI
staining and flow cytometry.
doi:10.1371/journal.pone.0031783.g002
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resulted in pronounced increase in apoptosis. Parallel study was
also performed with normal bone marrow mononuclear cells. The
DIM regimen induced relatively little apoptosis in normal bone
marrow mononuclear cells (Fig. 2d). Together, these findings
indicate that DIM selectively kills human leukemia cell lines and
primary leukemia cells but not normal hematopoietic cells.
DIM-induced apoptosis is associated with the caspase-
independent inactivation of Akt and activation of JNK
To determine whether any of these perturbations mediated by
DIM were secondary to caspase-mediated processes, U937 cells
were treated with 80 mM DIM in the presence of the broad-
spectrum caspase inhibitor Z-VAD-FMK at 20 mM. Addition of
Z-VAD-FMK, which abrogated DIM-induced apoptosis, PARP
degradation, and caspases activation (Fig. 3a and 3b), failed to
protect cells from DIM-mediated down-regulation of Mcl-1 and
up-regulation of p21 (Fig. 3c). Similarly, Z-VAD-FMK did not
attenuate DIM-mediated Akt inactivation and JNK activation
(Fig. 3d). Together, these findings suggest that DIM-mediated Akt
inactivation, JNK activation, Mcl-1 down-regulation, and p21
up-regulation do not simply reflect activation of the caspase
cascade.
Akt inactivation plays an important functional role in
DIM-mediated apoptosis
To understand the functional role of Akt inactivation in DIM-
induced apoptosis, U937 cells were pretreated with PI3K inhibitor
LY294002 for 1 h, followed by treatment with DIM for 24 h, and
apoptosis was monitored. As shown in Fig. 4a, co-administration
of a nontoxic concentration of LY294002 (i.e. 20 mM) with a
modestly toxic concentration of DIM (40 mM, ,25% apoptosis at
24 h) resulted a pronounced increase in apoptosis (,60% at 24 h).
Western blot analysis demonstrated that co-administration of DIM
and LY294002 resulted in pronounced increase in caspases
activation and PARP degradation (Fig. 4b). Combined treatment
with DIM and LY294002 also resulted in potentiation of Mcl-1
down-regulation, Akt inactivation and pronounced increase in
JNK activation (Fig. 4c). Together, these findings suggest that
inactivation of Akt plays a critical role in DIM-induced apoptosis
in human leukemia cells.
To further assess the functional significance of Akt inactivation
in DIM-mediated lethality, U937 cells ectopically expressing Akt-
CA and Akt-DN were employed. As shown in Fig. 4d, Akt-CA
cells were markedly less sensitive to DIM-induced apoptosis than
pcDNA3.1 vector control cells (p,0.01). However, DIM-induced
apoptosis in Akt-DN cells is similar to that in pcDNA3.1 control
Figure 3. Effects of inhibition of caspases by Z-VAD-FMK on apoptosis, expression of Mcl-1 and p21, and phosphorylation of Akt
and JNK. U937 cells were pretreated with the caspase inhibitor Z-VAD-FMK (20 mM) for 1 h, followed by treatment with 80 mM DIM for 12 h and
24 h. (a) Cells were stained with Annexin V/PI, and apoptosis was determined using flow cytometry. **Values for cells treated with DIM and Z-VAD-
FMK were significantly reduced compared to values obtained for DIM alone by Student’s t-test, p,0.01. (b–d) Total protein extracts were prepared
and subjected to Western blot assay using antibodies as indicated.
doi:10.1371/journal.pone.0031783.g003
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effective in triggering caspases activation and PARP degradation
in Akt-CA cells compared to pcDNA3.1 vector control cells and
Akt-DN cells (Fig. 4e). In addition, enforced activation of Akt
effectively blocked DIM-mediated Mcl-1 down-regulation (Fig. 4f).
Western blot analysis displayed marked increase in levels of total
and phospho-Akt in Akt-CA cells. DIM failed to induce
inactivation of Akt in these Akt-CA cells (Fig. 4f). Interestingly,
the ability of DIM to induce JNK activation was essentially
abrogated in Akt-CA cells (Fig. 4f), indicating that activation of
JNK mediated by DIM depends upon inactivation of Akt.
JNK activation plays an important functional role in DIM-
mediated apoptosis
To understand the functional significance of JNK activation in
DIM-induced apoptosis, both pharmacologic and genetic ap-
proaches were employed. Pretreatment with JNK inhibitor
SP600125 (i.e. 10 mM) essentially abrogated DIM-induced
apoptosis (Fig. 5a), caspases activation, and PARP degradation
(Fig. 5b). Co-administration of SP600125 also blocked Mcl-1
down-regulation and effectively diminished phosphorylation of
JNK mediated by DIM (Fig. 5c). To further confirm the functional
role of JNK in DIM-induced apoptosis, a genetic approach
utilizing JNK1 siRNA was employed. As shown in Fig. 5d,
transient transfection of U937 cells with JNK1 siRNA reduced
expression of JNK1, and resulted in a significant reduction in
DIM-mediated apoptosis. Collectively, these findings indicate that
DIM-induced JNK activation plays an important functional role in
DIM-related lethality.
DIM inhibits growth of a U937 tumor xenograft in
immunodeficient Mice
Finally, we evaluated whether our in vitro observations could be
translated into an animal model system in vivo. To address this
issue, NOD/SCID mice were inoculated in the flank with U937
human leukemia cells, after which mice were treated daily
intraperitoneally with either vehicle or DIM (50 mg/kg) for 20
days and tumors were measured. As shown in Fig. 6a, treatment
Figure 4. Effects of PI3K inhibitor, LY294002 (LY) and genetic activation of Akt on apoptosis induced by DIM. U937 cells were
pretreated with 20 mM of LY for 1 h, followed by the addition of 40 mM of DIM for 24 h. (a) Cells were stained with Annexin V/PI, and apoptosis was
determined using flow cytometry. **Values for cells treated with DIM and LY were significantly greater than those for cells treated with DIM alone by
Student’s t-test; p,0.01. (b–c) Total cellular extracts were prepared and subjected to Western blot analysis using antibodies as indicated. (d) U937
cells were stably transfected with an empty vector (pcDNA3.1), Akt-CA, and Akt-DN. Cells were treated with 80 mM of DIM for 24 h, after which
apoptosis was analysed using Annexin V/PI assay. **Values for Akt-CA cells treated with DIM were significantly decreased compared to those for
pcDNA3.1 cells by Student’s t-test, p,0.01. (e–f) Total cellular extracts were prepared and subjected to Western blot analysis using antibodies as
indicated.
doi:10.1371/journal.pone.0031783.g004
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U937 xenograft (p,0.01 compared with vehicle control), whereas
20 days following drug exposure no statistically significant change
in body weight was noted comparing vehicle control (Fig. 6b),
suggesting that no severe toxicity was observed. Tumors exposed
to DIM compared with vehicle control exhibited a reduced
number of cells per field under H&E staining, with signs of
necrosis with infiltration of inflammatory cells (i.e. phagocytic
cells), fibrosis, as well as apoptotic regions (Fig. 6c top panels).
Moreover, treatment with DIM resulted in a striking induction of
apoptosis in tumor cells determined by TUNEL analysis (Fig. 6c
middle panels). Exposure to DIM also caused marked increase in
immunoreactivity for the cleaved caspase-3 (Fig. 6c bottom
panels).
Lastly, we performed the immunohistochemistry analysis to
evaluate the expression of Mcl-1, phospho-Akt, and phospho-JNK
in tissue sections of U937 xenografts. As expected, tumors from
vehicle-treated control mice stained strongly for Mcl-1 and
phospho-Akt, which were immunolocalized to the cytoplasm of
cancer cells. Treatment with DIM resulted in markedly decrease
in expression of Mcl-1 (Fig. 6d top panels) and phospho-Akt in
tissue sections of tumors (Fig. 6d middle panels). Furthermore,
immunostaining of tumors from mice treated with DIM showed
marked increase in phospho-JNK (Fig. 6d bottom panels).
Collectively, these findings demonstrated that DIM administration
significantly inhibited U937 xenograft growth without causing any
side effects to the mice. DIM-mediated antileukemic activity in vivo
is associated with inactivation of Akt and activation of JNK.
Discussion
The present study shows that exposure of U937 human
leukemia cells resulted in increase in apoptosis in dose- and
time-dependent manners. In addition, our results provide
mechanistic information, for the first time, how DIM exerts its
proapoptotic effects on human leukemia cells (i.e. by inhibiting
phosphorylation of Akt and expression of Mcl-1, and by inducing
phosphorylation of JNK and the expression of p21). Experimental
Figure 5. Inhibition of JNK significantly protect cells from DIM-induced apoptosis. U937 cells were pretreated with 10 mM of JNK inhibitor,
SP600125 (SP), for 1 h, followed by the addition of 80 mM of DIM for 24 h. (a) Cells were stained with Annexin V/PI, and apoptosis was determined
using flow cytometry. **Values for cells treated with DIM and SP were significantly less than those obtained for cells treated with DIM alone by
Student’s t-test, p,0.01. (b–c) Total cellular extracts were prepared and subjected to Western blot assay using antibodies as indicated. (d) U937 cells
were transfected with JNK1 siRNA oligonucleotides or controls and incubated for 24 h at 37uC, after which cells were treated with 80 mM of DIM for
24 h. Apoptosis was determined using the Annexin V/PI assay. **Values for cells treated with DIM after transfection with JNK1 siRNA were
significantly decreased compared to those for control cells treated with DIM by Student’s t-test; p,0.01. Total cellular extracts were prepared and
subjected to Western blot analysis using antibodies against JNK1.
doi:10.1371/journal.pone.0031783.g005
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cancer cells including breast and prostate cancer cells through
different cell signaling pathways including NF-kB, Akt, MAPK,
p53, AR, and ER pathways [22], [24], [25]. Presently, no
information is available concerning the functional roles of the Akt
and JNK pathways in mediating in DIM-induced lethality,
particularly in malignant hematopoietic cells. The results of the
present study demonstrate that Akt inactivation and JNK
activation play key functional contributions in caspase activation
and subsequent lethality.
Akt is a serine–threonine kinase, which has been shown to be
activated in various cancers [26]. Akt plays a critical role in cell
survival through multiple downstream targets [27], [28]. Akt is
activated by PI3K, which in turn is regulated by the PTEN
phosphatase [29], mutations of which are among the most
commonly encountered in human cancers [30]. Akt activation
generally involves PTEN inactivation [31], and results in
attenuation of lethality [32]. The present findings show that
DIM exposure resulted in diminished Akt phosphorylation. While
it would be tempting to attribute this phenomenon to PTEN
activation, the fact that U937 cells do not express wild-type PTEN
argues against this notion [33]. A more likely possibility is that
DIM, through a mechanism not yet elucidated blocks the actions
of PI3K. The finding that LY294002, an inhibitor of PI3K,
enhanced DIM-mediated inhibition of Akt and lethality is
potentially consistent with this hypothesis. It should also be noted
that various stimuli induce apoptosis by different mechanisms
linked between Akt inactivation and caspase activation. The
caspase-dependent down-regulation of Akt is a well-described
positive feedback regulation. For example, previous study
demonstrated that 4-Hydroxynonenal (HNE)-mediated Akt inac-
tivation was caspase-3-dependent [34]. However, our previous
results indicate that inactivation of Akt by 2-methoxyestradiol does
not simply represent a secondary, caspase-dependent event [35].
In this study, co-treatment of cells with the caspase inhibitor Z-
VAD-FMK failed to prevent Akt inactivation. Such findings
Figure 6. In vivo antileukemic activity of DIM in U937 xenografts. 20 NOD/SCID mice were inoculated with U937 cells (2610
6 cells/mouse,
i.p.) and randomly divided into two groups (10/group) for treatment with DIM (50 mg/kg, i.p., daily, five times per week) or with vehicle control
solvent. (a) Average tumor volume in vehicle control mice and mice treated with 50 mg/kg DIM. P,0.01, significantly different compared with vehicle
control by Student’s t-test. (b) body weight changes of mice during the 20 days of study. (c) At the 20 days after DIM treatment, the tumors were
excised and subjected to H&E staining for determination of pathological evaluation, TUNEL assay for determination of apoptosis, and
immunohistochemical staining to determine Cleavage-caspase-3 immunoreactivity. Original magnification6400. (d) After treatment with DIM, tumor
tissues were sectioned and subjected to immunohistochemistry using anbibodies as indicated.
doi:10.1371/journal.pone.0031783.g006
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a secondary caspase- dependent event.
A number of evidence suggests that in human leukemia cells,
DIM-induced Akt inactivation plays a critical role in DIM-
mediated lethality. First, co-administration of LY294002 signifi-
cantly enhanced DIM-mediated caspases activation and apoptosis.
Second, enforced activation of Akt largely reversed the lethal
consequences of DIM. Particularly, DIM exposure resulted in
down-regulation of Mcl-1, an anti-apoptotic protein that may play
an important role in regulating apoptosis in malignant hemato-
poietic cells [36]. Mcl-1 has a short half-life and is a highly
regulated protein, induced by a wide range of survival signals and
rapidly down regulated during apoptosis [37]. Although the
precise mechanism underlying the Mcl-1 reduction upon DIM
treatment remains to be elucidated, interventions disabling Mcl-1
may be an optimal way to kill leukemia cells. It has been reported
that the anti-apoptotic gene Mcl-1 is up-regulated by the PI3K/
Akt signaling pathway [38], and down-regulation of Mcl-1 by
inhibition of PI3K/Akt pathway is required for cell death [39].
The finding that enforced activation of Akt largely blocked DIM-
mediated down-regulation of Mcl-1 may significantly contribute to
DIM-mediated lethality. However, additional mechanistic studies
are required to demonstrate the causative role of Mcl-1 in DIM
induced lethality in leukemia.
Induction of apoptosis was also associated with activation of
JNK pathway. Engagement of the SEK/JNK pathway has been
shown to play a key functional role in the lethal effects of diverse
cytotoxic stimuli, including inflammation and oxidative stress [40].
In fact, the net balance between cytoprotective (e.g. ERK) and
stress-related (e.g. JNK) signaling may play a critical role in cell
survival and death decisions [41]. The finding that pharmacologic
and genetic interruption of the JNK pathway attenuated DIM-
mediated lethality indicates that stress pathway play a critical role
in apoptosis induction by this agent. The mechanism by which
oxidative stress triggers JNK activation is not known with
certainty, but may involve release from GSH-mediated inhibitory
effects, or alternatively, perturbations in thioredoxin, leading to
activation of ASK-1 (apoptosis signal-regulating kinase-1), of
which JNK is a downstream target [42], [43]. Interestingly,
ectopic expression of Akt not only blocked DIM-mediated caspases
activation and apoptosis but also prevented the striking increase in
JNK activation, raising the possibility that one of the mechanisms
by which Akt protects cells from DIM lethality is by opposing JNK
activation. Evidence that the Akt-mediated inhibition of SEK1
and/or ASK1 may act as a negative regulation of the JNK
pathway through Akt-dependent induction of specific JNK-
interacting protein (JIP) provides a possible explanation for this
phenomenon [44]. Lastly, the observation that pharmacologic or
genetic interruption of the JNK pathway attenuated DIM-
mediated caspases activation and lethality demonstrates an
important functional role for this stress pathway in triggering the
cell death program. Such findings are compatible with previous
reports suggesting a direct role for JNK activation in promoting
cytochrome c release from the mitochondria [45].
Our present study has revealed that DIM causes up-regulation
of Cip/p21 expression in human leukemia cells. p21 protein is an
inhibitor of cyclin-dependent kinase (CDK) and plays an
important role in regulating CDK activity and cell cycle
progression in response to a wide variety of stimuli [46]. In
addition to normal cell cycle progression, p21 has been postulated
to participate in growth suppression and apoptosis through a p53-
dependent or –independent pathway following stress and induc-
tion of p21 may cause cell cycle arrest [47], [48]. In a recent study,
DIM has been shown to inhibit cell growth and induce G1 phase
cell cycle arrest in human breast cancer cells through Cip1/p21
up-regulation [21]. Consistent with this result, DIM-mediated
apoptosis in human leukemia cells may be associated with Cip/
p21 up-regulation and cell cycle arrest. Additional mechanistic
studies, however, are required in future to elucidate how Cip1/
p21 plays a role in DIM-induced apoptosis in human leukemia
cells.
Our study reported that DIM induces apoptosis in diverse
human leukemia cell lines (i.e. U937, Jurkat, and HL-60) and
primary human AML blast cells, and cell-signaling pathways
including Akt inactivation and JNK activation may be involved in
these events. However, it is still unclear whether the underlying
mechanism of apoptosis in vitro is identical to those in vivo. Our
present results showed that treatment with DIM could inhibit
tumor growth in U937 tumor xenograft model that could be
mechanistically linked with inactivation of Akt and activation of
JNK. These results further confirmed that inactivation of Akt and
activation of JNK could play an important role in DIM-induced
apoptosis in vivo.
In summary, the present study has provided evidence that DIM
induces human leukemia cell death with caspases activation and
PARP cleavage, and that DIM-induced apoptosis proceeds via
inactivation of Akt, activation of JNK, and down-regulation of
Mcl-1. The data presented here suggest that Akt and JNK
signaling pathways may represent attractive targets for DIM-
induced apoptosis in human leukemia cells in vitro and in vivo. The
results of the present study could have important implications for
the incorporation of agents such as DIM into the chemopreventive
or therapeutic intervention against leukemia and possibly other
hematologic malignancies.
Materials and Methods
Chemicals and reagents
DIM was purchased from Sigma (St Louis, MO). LY294002,
SP600125, and Z-VAD-FMK were from EMD Biosciences (La
Jolla, CA). Antibodies against Akt, phospho-JNK, JNK, and b-
actin were from Santa Cruz (Santa Cruz, CA). Cleaved-caspase-3,
Cleaved-caspase-7, Cleaved-capase-9, and phospho-Akt (Ser473)
were from Cell Signaling (Beverly, MA). Mcl-1 and p21 were from
PharMingen (San Diego, CA). PARP was from Biomol (Plymouth
Meeting, PA). Caspase-8 was from Alexis (Carlsbad, CA).
Cell culture and transfection
U937, HL-60, and Jurkat cells were provided by American
Type Culture Collection (ATCC, Manassas, VA) and maintained
in RPMI 1640 medium containing 10% fetal bovine serum (FBS).
The constitutive active form of Akt (Akt-CA) and the dominant
negative Akt mutant (Akt-DN) were kindly provided by Dr.
Richard Roth (Stanford University, School of Medicine, Stanford,
CA), and were subcloned into the pcDNA3.1. U937 cells were
stably transfected with Akt-CA and Akt-DN using the Amaxa
nucleofector
TM (Koeln, Germany) as recommended by the
manufacturer. Stable single cell clones were selected in the
presence of 400 mg/ml of geneticin. Thereafter, the expression of
Akt from each cell clone was analyzed by Western blot analysis.
Peripheral-blood samples for the in vitro studies were obtained
from 15 patients with newly diagnosed or recurrent acute myeloid
leukemia (AML) after informed consent. The percentage of AML
cells from each patient were greater than 20%. According to
French-American-British (FAB) classification system, 4 patients are
M2, 5 patients are M4, and 6 patients are M5. Approval was
obtained from the Southwest Hospital (Chongqing, China)
institutional review board for these studies. AML blasts were
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(Sigma Diagnostics, St Louis, MO) at 400 g for 30 minutes.
Isolated mononuclear cells were washed and assayed for total
number and viability using trypan blue exclusion. Cells were
suspended at 8610
5/mL for treatment. Fresh normal bone
marrow mononuclear cells were purchased from Allcells (Emer-
yvill, CA). After washing and enumerating, cells were suspended at
8610
5/mL prior to treatment.
RNA interference and transfection
U937cells (1.5610
6) were transfected with 1 mg JNK1-annealed
dsRNAi oligonucleotide 59-CGUGGGAUUUAUGGUCUGUG-
TT-39/39-TTGCACCUAAAUACCAGACAC-59 (Orbigen, San
Diego, CA, USA) using the Amaxa nucleofectort (Koeln,
Germany) as recommended by the manufacturer. After incubation
at 37uC for 24 h, transfected cells were treated with DIM, and
subjected to determination of apoptosis and JNK1 expression
using Annexin V/PI and flow cytometry and Western blot
analysis.
Assessment of apoptosis
The extent of apoptosis in leukemia cells was evaluated by flow
cytometric analysis using FITC conjugated Annexin V/propidium
iodide (BD PharMingen, San Diego, CA) staining according to the
manufacturer’s instructions. Both early apoptotic (Annexin V-
positive, PI-negative) and late apoptotic (Annexin V-positive and
PI-positive) cells were included in cell death determinations.
Western blot analysis
The total cellular samples were washed twice with ice-cold PBS
and lysed in 16NuPAGE LDS sample buffer supplemented with
50 mM dithiothreitol. The protein concentration was determined
using Coomassie Protein Assay Reagent (Pierce, Rockford, IL).
30 mg of sample proteins were separated by SDS-PAGE and
transferred to nitrocellulose membrane. Membranes were blocked
with 5% fat-free dry milk in 16 Tris-buffered saline (TBS) and
incubated with antibodies. Protein bands were detected by
incubating with horseradish peroxidase-conjugated antibodies
(Kirkegaard and Perry Laboratories, Gaithersburg, MD) and
visualized with enhanced chemiluminescence reagent (Perkin
Elmer, Boston, MA).
Xenograft assay
NOD/SCID (severe combined immunedeficient) mice (5 weeks
old) were purchased from Vital River Laboratories (VRL, Beijing,
China). All animal studies were conducted according to protocols
approved by the Institutional Animal Care and Use Committee
(IACUC) of Third Military Medical University (Approval ID:
2009020014). U937 cells (2610
6/0.2 mL/mouse) were suspended
in sterile PBS and injected s.c. into the right flank of the mice.
Mice were randomized into two groups (10 mice/group). Three
days after tumor inoculation, the treatment group received DIM
(50 mg/kg, i.p., five times per week). The control group received
an equal volume of solvent control. Tumor size and body weight
were measured after treatment at various time intervals through-
out the study. At the termination of the experiment, mice were
sacrificed at 24 h after the last administration. The tumors were
excised and weighed. Tumors were collected at selected times and
fixed in paraformaldehyde. Paraffin-embedded tissues were
sectioned and processed for TUNEL staining and immunohisto-
chemical staining.
TUNEL assay
The apoptotic cells in tissue samples were detected using an In
Situ Cell Death Detection kit (Roche Diagnostics, Mannheim,
Germany) according to the manufacturer’s manual. After
deparaffinization and permeabilization, the tissue sections were
incubated in proteinase K for 15 min at room temperature. The
sections were then incubated with the TUNEL reaction mixture
that contains terminal deoxynucleotidyl transferase (TdT) and
fluorescein-dUTP at 37uC for 1 h. After washing three times with
PBS, the sections were incubated with the Converter-POD which
contains anti-fluorescein antibody conjugated with horse-radish
peroxidase (POD) at room temperature for 30 minutes. After
washing three times with PBS, the sections were incubated with
0.05% 3-39-diaminobenzidine tetrahydrochloride (DAB) and
analyzed under light microscope.
Histological and immunohistochemical evaluation
At the termination of experiments, tumor tissues from
representative mice were sectioned, embedded in paraffin, and
stained with hematoxylin and eosin for histopathologic evaluation.
For immunohistochemical analysis, tissue sections 4 mmi n
thickness were dewaxed and rehydrated in xylene and graded
alcohols. Antigen retrieval was performed with 0.01 M citrate
buffer at pH 6.0 for 20 min in a 95uC water bath. Slides were
allowed to cool for another 20 min, followed by sequential rinsing
in PBS and TBS-T buffer. Endogenous peroxidase activity was
quenched by incubation in TBS-T containing 3% hydrogen
peroxide. After washing in TBS-T for three times and blocking
with 10% goat serum for 1 h, sections were incubated with
primary antibodies, washed three times in PBS, incubated with
biotinylated secondary antibody for 1 h, followed by incubation
with a streptavidin-peroxidase complex for another 1 h. After
three additional washes in PBS, diaminobenzidine working
solution was applied. Finally, the slides were counterstained in
hematoxylin.
Statistical analysis
Tumor volumes, body weights, and percentage of apoptotic cells
were represented as mean 6 SD. The statistical significance of the
difference between control and UA-treated groups was evaluated
using Student’s t test. p,0.05 or p,0.01 were considered
significant.
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